Detalhe da pesquisa
1.
Dose-Blinded Myosin Inhibition in Patients With Obstructive Hypertrophic Cardiomyopathy Referred for Septal Reduction Therapy: Outcomes Through 32 Weeks.
Circulation
; 147(11): 850-863, 2023 03 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-36335531
2.
Study design and rationale of VALOR-HCM: evaluation of mavacamten in adults with symptomatic obstructive hypertrophic cardiomyopathy who are eligible for septal reduction therapy.
Am Heart J
; 239: 80-89, 2021 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-34038706
3.
Mavacamten in Patients With Hypertrophic Cardiomyopathy Referred for Septal Reduction: Week 56 Results From the VALOR-HCM Randomized Clinical Trial.
JAMA Cardiol
; 8(10): 968-977, 2023 Oct 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37639243
4.
Myosin Inhibition in Patients With Obstructive Hypertrophic Cardiomyopathy Referred for Septal Reduction Therapy.
J Am Coll Cardiol
; 80(2): 95-108, 2022 07 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-35798455